Background and objectives: The purpose of this systematic review was to evaluate the safety and efficacy of autologous hematopoietic cell transplantation in patients with progressive multiple sclerosis (MS) refractory to conventional medical treatment.
Methods: Eight case series met our a priori inclusion criteria for the primary outcome of progression-free survival. Individual study quality was rated using an 11-item scale for case series. The strength of the overall body of evidence for each outcome was rated using a system developed by the ECRI Institute. Data from different studies were statistically combined using meta-analysis. An additional six studies were included for a summary of mortality and morbidity.
Results: For secondary progressive MS, immunoablative therapy with autologous bone marrow/peripheral blood stem cell transplantation was associated with higher progression-free survival (up to 3 years following treatment) when using intermediate-intensity conditioning regimens compared with high-intensity conditioning regimens. The evidence was insufficient to determine whether the treatment was effective in patients with other types of MS. Treatment-related mortality was about 2.7%.
Conclusions: Patients with secondary progressive MS refractory to conventional medical treatment have longer progression-free survival following autologous stem cell transplantation with intermediate-intensity conditioning regimens than with high-intensity conditioning regimens.
AtkinsHFreedmanM. Immunoablative therapy as a treatment aggressive multiple sclerosis. Neurol Clin2005; 23: 273–300, ix.
6.
GriffithLMPavleticSZTyndallABredesonCNBowenJDChildsRW. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute—sponsored international workshop. Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant2005; 11: 862–870.
7.
Treadwell JT, Tregear SJ, Reston JT and Turkelson CM. A system for rating the stability and strength of medical evidence. BMC Med Res Methodol 2006; 6: 52. Available at: http://www.biomedcentral.com/1471–2288/6/52.
8.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials1986; 7: 177–188.
BorensteinMHedgesLHigginsJRothsteinH. Introduction to Meta-analysis. Hoboken, NJ: John Wiley & Sons, Inc, 2009.
11.
HigginsJPThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ2003; 327: 557–560.
12.
HigginsJPThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med2002; 21: 1539–1558.
13.
HigginsJPThompsonSG. Controlling the risk of spurious findings from meta-regression. Stat Med2004; 23: 1663–1682.
14.
NiXSOuyangJZhuWHWangCChenB. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant2006; 20: 485–489.
15.
XuJJiBXSuLDongHQSunXJLiuCY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl)2006; 119: 1851–1855.
16.
SaccardiRMancardiGLSolariABosiABruzziPDi BartolomeoP. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood2005; 105: 2601–2607.
17.
CapelloESaccardiRMurialdoAGualandiFPagliaiFBacigalupoA. Italian GITMO-Neuro Intergroup on ASCT for Multiple Sclerosis. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci2005; 26(Suppl 4): S200–S203.
18.
SaizABlancoYCarrerasEBerenguerJRoviraMPujolT. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology2004; 62: 282–284.
19.
CarrerasESaizAMarinPMartinezCRoviraMVillamorN. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica2003; 88: 306–314.
20.
FassasAAnagnostopoulosAKazisAKapinasKSakellariIKimiskidisV. Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. J Clin Immunol2000; 20: 24–30.
21.
SamijnJPte BoekhorstPAMondriaTvan DoomPAFlachHZvan der MecheFG. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry2006; 77: 46–50.
22.
BurtRKCohenBARussellESperoKJoshiAOyamaY. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood2003; 102: 2373–2378.
23.
NashRABowenJDMcSweeneyPAPavleticSZMaravillaKRParkMS. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood2003; 102: 2364–2372.
24.
Fagius J, Lundgren J and Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009; 15: 229–237.
25.
ShevchenkoYLNovikAAKuznetsovANAfanasievBVLisukovIAKozlovVA. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol2008; 36: 922–928.
26.
SaccardiRKozakTBocelli-TyndallCFassasAKazisAHavrdovaE. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler2006; 12: 814–823.
27.
EspigadoIMarin-NieblaARoviraMJuliaARodriguezJMAltesA. Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience. Transplant Proc2003; 35: 742–743.
28.
KozakTHavrdovaEPit'haJGregoraEPytlikRMaaloufovaJ. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc2001; 33: 2179–2181.
29.
OpenshawHLundBTKashyapAAtkinsonRSniecinskiIWeinerLP. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant2000; 6: 563–575.
30.
FassasAPasswegJRAnagnostopoulosAKazisAKozakTHavrdovaE. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol2002; 249: 1088–1097.
31.
BurtRKLohYPearceWBeoharNBarrWGCraigR. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA2008; 299: 925–936.
32.
JoyJEJohnstonRBJr. Multiple Sclerosis: Current Status and Strategies for the Future. National Academy Press, 2001.
